Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 21 citing articles:

The JAK/STAT signaling pathway: from bench to clinic
Xiaoyi Hu, Jing Li, Maorong Fu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1450
Prognoses and genomic analyses of proteasome 26S subunit, ATPase (PSMC) family genes in clinical breast cancer
Tzu‐Jen Kao, Chung-Che Wu, Nam Nhut Phan, et al.
Aging (2021) Vol. 13, Iss. 14, pp. 17970-17970
Open Access | Times Cited: 88
Potential Prognostic Biomarkers of NIMA (Never in Mitosis, Gene A)-Related Kinase (NEK) Family Members in Breast Cancer
Gangga Anuraga, Wei‐Jan Wang, Nam Nhut Phan, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 11, pp. 1089-1089
Open Access | Times Cited: 59
Regulation of the JAK/STAT signaling pathway: The promising targets for cardiovascular disease
Qiuyu Pang, Lu You, Xiangmin Meng, et al.
Biochemical Pharmacology (2023) Vol. 213, pp. 115587-115587
Closed Access | Times Cited: 25
Potential Therapeutic and Prognostic Values of LSM Family Genes in Breast Cancer
Hoang Dang Khoa Ta, Wei‐Jan Wang, Nam Nhut Phan, et al.
Cancers (2021) Vol. 13, Iss. 19, pp. 4902-4902
Open Access | Times Cited: 37
Prognostic and Genomic Analysis of Proteasome 20S Subunit Alpha (PSMA) Family Members in Breast Cancer
Chung-Chieh Chiao, Yen-Hsi Liu, Nam Nhut Phan, et al.
Diagnostics (2021) Vol. 11, Iss. 12, pp. 2220-2220
Open Access | Times Cited: 36
Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy
Xiaohuan Wei, Yuanyuan Liu
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 5
Prognostic and immune infiltration signatures of proteasome 26S subunit, non-ATPase (PSMD) family genes in breast cancer patients
Do Thi Minh Xuan, Chung-Che Wu, Tzu‐Jen Kao, et al.
Aging (2021) Vol. 13, Iss. 22, pp. 24882-24913
Open Access | Times Cited: 29
Transcriptomics based multi-dimensional characterization and drug screen in esophageal squamous cell carcinoma
Yin Li, Fengkai Xu, Fanghua Chen, et al.
EBioMedicine (2021) Vol. 70, pp. 103510-103510
Open Access | Times Cited: 27
Analysis of LAGEs Family Gene Signature and Prognostic Relevance in Breast Cancer
Hoang Dang Khoa Ta, Wanchun Tang, Nam Nhut Phan, et al.
Diagnostics (2021) Vol. 11, Iss. 4, pp. 726-726
Open Access | Times Cited: 17
Circadian rhythm-related factors of PER and CRY family genes function as novel therapeutic targets and prognostic biomarkers in lung adenocarcinoma
Chin‐Chou Wang, Wei-Hsun Lin, Su‐Chi Ku, et al.
Aging (2022) Vol. 14, Iss. 22, pp. 9056-9089
Open Access | Times Cited: 11
Expression Profiles and Prognostic Value of FABPs in Colorectal Adenocarcinomas
Fidelia Berenice Prayugo, Tzu‐Jen Kao, Gangga Anuraga, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1460-1460
Open Access | Times Cited: 14
Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis – an option beyond ruxolitinib
Chandan Saha, Claire Harrison
Expert Review of Hematology (2022) Vol. 15, Iss. 7, pp. 583-595
Closed Access | Times Cited: 9
Comprehensive analysis of prognostic significance of cadherin (CDH) gene family in breast cancer
Su‐Chi Ku, Hsin-Liang Liu, Che‐Yu Su, et al.
Aging (2022), pp. 8498-8567
Open Access | Times Cited: 9
8-Hydroxydaidzein Downregulates JAK/STAT, MMP, Oxidative Phosphorylation, and PI3K/AKT Pathways in K562 Cells
Pei‐Shan Wu, Chih‐Yang Wang, Pin-Shern Chen, et al.
Biomedicines (2021) Vol. 9, Iss. 12, pp. 1907-1907
Open Access | Times Cited: 11
Multiple Comprehensive Analyses Identify Lysine Demethylase KDM as a Potential Therapeutic Target for Pancreatic Cancer
Wan‐Jou Shen, Hsuan-Min Kao, Chih‐Yang Wang, et al.
International Journal of Medical Sciences (2024) Vol. 21, Iss. 11, pp. 2158-2169
Open Access | Times Cited: 1
Novel Potential Therapeutic Targets of PTPN Families for Lung Cancer
Chin‐Chou Wang, Wan‐Jou Shen, Gangga Anuraga, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 12, pp. 1947-1947
Open Access | Times Cited: 7
Penetrating Exploration of Prognostic Correlations of the FKBP Gene Family with Lung Adenocarcinoma
Chin‐Chou Wang, Wan‐Jou Shen, Gangga Anuraga, et al.
Journal of Personalized Medicine (2022) Vol. 13, Iss. 1, pp. 49-49
Open Access | Times Cited: 7
Comprehensive analysis of bulk and single-cell RNA sequencing data reveals Schlafen-5 (SLFN5) as a novel prognosis and immunity
Yueh‐Jung Wu, Chung-Chieh Chiao, Po-Kai Chuang, et al.
International Journal of Medical Sciences (2024) Vol. 21, Iss. 12, pp. 2348-2364
Open Access
Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
Satoru Miyazaki, Masato Kitazawa, Satoshi Nakamura, et al.
Molecular Oncology (2024)
Open Access
Applying a Gene Reversal Rate Computational Methodology to Identify Drugs for a Rare Cancer: Inflammatory Breast Cancer
Xiaojia Ji, Kevin P. Williams, Weifan Zheng
Cancer Informatics (2023) Vol. 22
Open Access
Page 1

Scroll to top